Background: SEN virus (SENV) and Torque teno virus (TTV) are blood born viruses. Their effect on the development and progress of liver diseases is still unclear. The aim of this study was to determine the prevalence and effect of SENV and TTV among chronic hepatitis C (CHC) patients.
Introduction
HCV infection is a public health problem in Egypt, the country with the highest prevalence rate worldwide. With the introduction of the direct acting antivirals (DAAs) active against HCV in 2014, the story has seemed to come to the end. In order to achieve the objective of eradication of HCV by 2030, many DAAs are available and are easily accessible in Egypt including sofosbuvir, daclatasvir, simeprevir, idvipasivir, ombitasvir, paritaprevir and ritonavir. Guidelines for treatment of various categories of Egyptian HCV patients have been developed by the National Committee for Control of Viral Hepatitis (NCCVH) and are being regularly updated [1] . For better management of CHC patients it is important to assess the impact of concomitant infections on the clinical course and the progression of the disease.
In the last few years, SENV and TTV have been described as new blood-borne, hepatotropic viral agents with possible hepatic pathogenicity [2] .
SEN virus (SENV) is the latest virus proposed as a cause of unknown hepatitis cases. The virus is a circular, single-stranded DNA virus, with around 3800 nucleotides long and nearly 26 nm size. It is non-enveloped and has a minimum of three ORFs [3] . In the base of investigations on ORF1 sequences, SENV has been classified in the Anellovirusgenus [4] . Nine genotypes (A to I) with about 25% differences in nucleotide sequence are known [5] . Among the nine genotypes, SENV-D and SENV-H genotypes are the most frequently isolated from cases of (non-A to E) hepatitis. However, they are also frequent in the sera of healthy blood donors [6] . SENV is ubiquitous with distinct geographic variation [7] .
TTV has been discovered in 1997 (Japan) in the bloodstream of a patient with post-transfusion hepatitis. It was the first human virus with a singlestranded circular DNA genome to be identified [8] . TTV has recently been classified as the Alphatorque virus genus within the Anelloviridae family by the International Committee on Taxonomy of Viruses (ICTV). Thus far, five main genetic groups (Groups 1-5) involving at least 39 genotypes have been identified based on phylogenetic analysis.
SENV and TTV are identified among wide ranges of populations including intravenous drug users [9] , hemophilic and thalassemic patients [10] , patients on maintenance hemodialysis [11] , HIV positive [12] and patients with hepatic disease [8] . Lin et al. have reported that SEN-V is sensitive to interferon (IFN) therapy [13] . After the stoppage of IFN therapy on HCV patients co-infected with SENV, the later was eradicated in 77% while the former was eliminated in 38% of patients. These reflect the higher sensitivity of SENV virus to IFN therapy than that of HCV. Combined treatment with ribavirin (RBV) therapy does not affect SENV response to IFN therapy in contrast to what occurs in HCV infection [14] .
The response rate (62-83%) of treatment with INF of cases of CHC co-infected with TTV is the same whether RBV is added or not [15] . Moreover, the response of HCV to IFN/RBV therapy is not influenced by TTV concurrent infection [16] .Additionally, the impact of SENV and TTV on the development of and progression of hepatic diseases is controversial [17] .
We carried out this study to determine the prevalence of both SENV and TTV among HCV infected individuals in Egyptian patients and to detect their clinical significance.
Patients and methods

Study design
This cross sectional study was done in the Medical Microbiology and Immunology Department, Zagazig, Faculty of Medicine and the University Hospitals. The study protocol was reviewed and approved by the Institutional Review Board (IRB). A written informed consent was obtained from all patients.
Patients and samples
Two hundred patients with chronic CHC infection (positive quantitative PCR for HCV for more than 6 months) were enrolled in the study. They were HBs-Ag negative and had no history of other viral or autoimmune hepatitis. They were 92 males and 108 females with ages ranging from (29-90) years, (M±SD: 55.2±14.5). For all patients, complete clinical assessmentand abdominal ultrasonography were done.
Blood samples were collected and serum separated for liver function tests; aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin andbilirubin. All were measured by using (SAT 450 turbidimetric assay, ELitech, USA). Quantitative PCR for HCV was done by Taq Man Assay Reagents, Applied Biosystems (Thermo Fisher Scientific, USA), using the 7500 fast Real Time PCR system with lower limit of detection 15 IU/ml (the procedure and primers used according to Abate et al. [18] ). The remaining sera were stored at -80°C until used for SENV and TTV detection.
Extraction of DNA from serum DNA was extracted from 200 μL serum using Thermo Scientific, Gene JET Viral DNA and RNA Purification kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions.
Amplification and detection SENV. The following components was added for each 20μL reaction: 10μL DreamTaq Green PCR Master Mix (2X), 20 pmol of each primer (Thermo Fisher Scientific, USA) (sense primer for SENV-D, "5´-GTAACTTTGCGGTCAACTGCC-3´"; sense primer for SENV-H, "5´-GGTGCCCCTWGTYAGTT-GGCGGTT-3´" [W = A or T]; universal antisense primer,"5´-CCTCGGTTKSAAAKGTYTGATAGT-3´" [K = G or T, S = C or G, and Y= C or T]) [19] and 5 μL DNA template. They were amplified in a thermal cycler (Biometra, Germany) for 40 cycles. Each cycle consisted of denaturation at 95°C for 60 seconds, primer annealing at 55°C for 30 seconds, and extension at 72°C for 60 seconds, with a final extension step at 72°C for 10 minutes.
TTV. A 20 µl PCR mixture containing 10 μLDreamTaq Green PCR Master Mix (2X), 20 pmol of each primer(Thermo Fisher Scientific, USA) (Sense primer; "5´-GCTACGTCACTAACCACGTG-3´"& antisense primer; "5´-CTBCGGTGTGTAAACT-CACC-3´ [20] and 5 μL DNA template. It was amplified using a thermo-cycling program that consisted of an initial denaturation for 9 minutes at 95°C; and then 55 cycles of 20 seconds at 95°C, 20 seconds at 55°C, and 30 seconds at 72°C. Amplicons were also kept at 72°C for 5 minutes for further polymerization.
Statistical data analysis
The statistical analysis was performed using IBM SPSS Statistics, version 24 (IBM; Armonk, New York, USA). Continuous data were expressed as means ± standard deviation (SD) and compared using Student's T test. Categorical variables were expressed as percentage and compared using chi-square (χ 2 ) test and Fisher's exact probability test. A P value of ≤ 0.05 was considered significant
Results
Prevalence of SENV and TTV among chronic HCV patients
Out of 200 chronic HCV patients, 3 were positive for SENV-H demonstrated by the detection of a band of 230bp on gel electrophoresis. SENV-D was not detected in any case. Listed below are the clinical, physical, radiological and laboratory characteristics of the three cases from which SENV were identified.
Patient 1
A 60-year old male receiving furosemide, spironolactone, and lactulose. He had moderate ascites. Ultrasonography showed cirrhotic liver. The body mass index was 27. Hemoglobin level was 11.5 g/ dL, platelet count was 65×103 U/L and total leucocyte count was 2.4 ×103 U/L. The INR was 1.4. Liver function test results were: serum albumin 2.9 g/dL, total bilirubin 25.6 µmol/L, ALT 48U/L and AST 65 U/L, Alpha feto protein 20 ng/ml (ELISA kit; DiaMetra, Milano, Italy), antinuclear antibodies; negative (ANA ELISA kit, AESKULISA, Germany) and serum creatinine 0.9 µmol/L (SAT 450 turbidimetric assay, ELitech,USA). The patient was diagnosed to have ascites and was classified as Child Class B with Child Pugh Score 8 and MELD Score 12. He had no history of hemodialysis, positive history of blood transfusion (9 unit of blood), and positive history of previous surgery.
Virology testing revealed negative HBsAg and positive HCV G4a with a viral load of 5.3 log 10 (copies/mL) TaqMan Real Time PCR with lower limit of detection 15 IU/ml.
Patient 2
A 72 year-old female receiving furosemide, spironolactone, lactulose, liver support, vitamine K and rantidine. She had mild ascites. Ultrasonography showed cirrhosis and focal mass. The body mass index was 18. Hemoglobin level was 10.5 g/dL, platelet count was 92×103 U/L and total leucocyte count was 9×103 U/L. The INR was 1.7. Liver function test results were: serum albumin 2.4 g/dL, total bilirubin 29.07µmol/L, ALT 52U/L and AST 63U/L. Alpha feto protein 500 ng/ml (ELISA kit ;DiaMetra, Milano, Italy), antinuclear antibodies; negative (ANA ELISA kit, AESKULISA,Germany) and serum creatinine 0.9 µmol/L (by SAT 450 turbidimetric assay, ELitech, USA). The patient was diagnosed to have hepatocellular carcinoma and was classified as Child Class B with Child Pugh Score 9 and MELD Score 14.
She had no history of hemodialysis or surgery and positive history of blood transfusion (6 units). Virologic testing revealed negative HBsAg and positive HCV G4a with a viral load of 6.3 log 10 (copies/mL) TaqMan Real Time PCR with lower limit of detection 15 IU/ml.
Patient 3
A 53 year-old female receiving spironolactone, lactulose, liver support, vitamin K, rantidine and calcium supplement. Ultrasonography showed cirrhotic liver. The body mass index was 23. On examination she had hemoglobin level of 9 g/dL, platelet count of 110×103 U/L and total leucocyte count of 9×103 U/L. The INR was 1.2. Liver function test results were: serum albumin 3.3 g/dL, total bilirubin 22.2 µmol/l, ALT 47U/L and AST 54U/L. Alpha feto protein was 30ng /ml (ELISA kit;DiaMetra, Milano, Italy), antinuclear antibodies; negative(ANA ELISA kit, AESKULISA,Germany) and serum creatinine was 79.5 µmol/l (SAT 450 turbidimetric assay, ELitech,USA) The patient was diagnosed to have microcytic hypochromic anemia and was classified as Child Class B with Child Pugh Score 9 and MELD Score 14.
She had no history of hemodialysis or surgery, positive history of blood transfusion (4 units). Virologic testing revealed negative HBsAg and positive HCV G4a with a viral load of 6.14 log 10 (copies/ mL) TaqMan Real Time PCR with lower limit of detection 15 IU/ml. Out of 200 chronic HCV patients, 21 (10.5%) were positive for TTV as demonstrated by visualization of a band of 199 bp on gel. A. Among the studied CHC patients; there were 92 male and 108 female with mean age of 55.2. The level of HCV RNA log 10 by real time PCR ranged from (4.30-7.59) copies/mL. On ultrasonographic examination; cirrhosis and focal mass were found in 27.5% of patients and cirrhosis only was detected in 53.5% of them. while 14% of patients had periportal fibrosis. Regarding laboratory investigations; total bilirubin, direct bilirubin, ALT and AST levels were elevated in 32%, 29.5%, 64% and 61% of patients respectively. Regarding risk factors; positive history of blood transfusion, positive history of previous surgery, positive history of Tattooing were reported in 61%, 74.5% and 27% of patients respectively, as shown in Table 1 .
Comparing laboratory and ultrasonography findings
In 21 cases co-infected with (TTV&HCV) and 179 cases (HCV positive& TTV negative), there were no statistically significance difference between both groups (P>.05), as shown in Table 2 .
Comparing parental risk factors for TTV Between 21 cases co-infected with (TTV&HCV) and 179 cases (HCV positive& TTV negative). The history of blood transfusion and history of surgery were significantly higher in patients co-infected with (TTV& HCV) than the second group, as shown in Table 3 . HCV: hepatitis C virus, ALT: alanine aminotransferase, AST: aspartate-aminotransferase. 1 : Normal level ¡(0-1mg/dl), 2 : normal level (0-0.3 mg/dl), 3 : normal level (0-40U/L), 4 : normal level (0-37U/L), 5 : normal level (3.5-5g/dL). TTV: transfusion-transmitted virus, HCV: hepatitis C virus, ALT: alanine aminotransferase, AST: aspartate-aminotransferase. 1 : Normal level (0-1mg/dl), 2 : normal level (0-0.3 mg/dl), 3 : normal level (0-40U/L), 4 : normal level (0-37U/L). 
Discussion
Further achievements have been made to bring HCV to the era of eradication. After the approval of DAAs in 2011, the therapeutic revolution against HCV involves pangenotypic HCV therapy which is a regimen combining two or three, 2 nd generation DAAs. Duration of therapy is 8-16 weeks depending on the stage of fibrosis, genotype, baseline viral load, prior treatment history and pre-existing resistance-associated variants. Most of these combinations have a high antiviral potency, fair tolerance and a reduced pill burden [21] .
Contrary to studies carried out in Egypt or elsewhere, [11, [22] [23] [24] very low level of prevalence of SENV was identified in the current work. This can beattributed to technical or host factors. Technical factors include differences in the sensitivities of the assay systems [23] , or primers used. In 2015, Abuodeh et al., concluded that the extensive variation in sequence of SENV made it difficult to select a primer set that can detect all virus genotypes [25] . Human factors are based on the possibility of the ubiquitous distribution of SENV that could be affected by collaborations among behavioral, social, biological and climate factors [10] . Furthermore, the rate of clearance of SENV can contribute to variable rate of SENV among different populations. Umemura and colleagues in 2001, reported that about 77% of post transfusion infected patients have cleared the virus within 6 months after being infected and that 13% appeared to have chronic SEN virus infection [26] .
The three cases positive for SEN-V in the current work showed history of parenteral exposure through blood transfusion, tattoing and surgical procedures. These support the idea that SENV is transmitted via parental route.
The prevalence of TTV was 10.5% among CHC patients. Great variations in the prevalence of TTV have been reported in various studies. The prevalence of TTV infection in the current work falls within range reported before [27, 28] . However, it is lower than those identified in several other studies; 84.9% in Qatar, 90% in Pakistan and 47% in Taiwan [24] [25] 29] respectively. These variations can beattributed to differences in the quantity of viral DNA in the sera, different primers used, differences in the sensitivities of methods of detection, different study populations and different risk factors.
The prevalence of TTV was more in patients aged (50-70) years. This may be due to presence of large number of the patients in this study in this age group.
The statistically-significant differences as regards history of blood transfusion and history of previous operations in patients positive for TTV versus TTV negative patients (p-value <.05) support the idea that TTV is transmitted parentally. This was in agreement with other studies [7, [10] [11] which reported wide ranges of infection in intravenous drug users, hemophilic and thalassemic patients, patients on maintenance hemodialysis, HIV positive and patients with hepatic disease. The insignificant difference regarding age, gender can be attributed to characters of the study population. On the other hand, the insignificant difference as regards tattooing is due to small number of cases practicing this procedure.
This study found no statistically significant difference between TTV positive and TTV negative individuals regarding the level of AST, ALT, other laboratory and ultrasonography finding which agree with study of Bostan et al. [30] , but contrary to other studies [8, 31] . Rocchi et al. [32] attributed the pathologic role of TTV to the capability of some isolates to activate production of pro-inflammatory cytokines, thus accelerate the severity of inflammatory disorders.
Conclusion
The present study includes a small number of cases positive for SENV which does permit a definite conclusion. However, there was no significant correlation as regards the mean age or sex between TTV positive and TTV negative patients. TTV does not appear to have an impact on progression of hepatic diseases. The parenteral route seems to be critical in the transmission of TTV.
